Identify, develop and commercialize psychotropic drugs
Fabre-Kramer (Fabre-Kramer Pharmaceuticals, Inc.) development program features more efficient outsourced structure and accelerated timelines. FKP can economically and efficiently further develop these products, and then out-license them for the completion of development, registration, and commercialization. FKP has developed its pipeline of pharmaceutical products at costs far below those of major pharmaceutical companies.
Pipeline
Fabre-Kramer Products focus on the development of psychiatry and neurology. The pipeline consists of EXXUA™, FKO1MDD, FKBO1MD, FKWOOG, FKFO2SC, and FKFO1PD products majority of which are in advanced clinical development. The lead compound EXXUA™ expects approval in 2023.
Partnerships
As a virtual company, FKP forms partnerships with individual researchers, research institutions,
pharmaceutical as well as biotechnology companies, to license in molecules for development and further license them out for commercialization.
Fabre-Kramers expertise is concentrated around clinical development of compounds in the area of psychiatry and neurology.